Lauren Mastrocola Sells 5,188 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) insider Lauren Mastrocola sold 5,188 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $81.78, for a total value of $424,274.64. Following the sale, the insider now owns 5,613 shares in the company, valued at $459,031.14. The trade was a 48.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Praxis Precision Medicines Trading Down 6.7 %

NASDAQ:PRAX opened at $71.76 on Friday. The business’s fifty day moving average is $67.00 and its 200 day moving average is $55.01. Praxis Precision Medicines, Inc. has a 52-week low of $13.98 and a 52-week high of $86.93.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Wednesday, November 6th. The company reported ($2.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.74). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.53 million. During the same period in the previous year, the firm earned ($2.70) EPS. Research analysts forecast that Praxis Precision Medicines, Inc. will post -10.26 earnings per share for the current year.

Institutional Trading of Praxis Precision Medicines

Institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of Praxis Precision Medicines during the 1st quarter valued at $412,000. SG Americas Securities LLC purchased a new position in Praxis Precision Medicines during the first quarter worth about $150,000. Vanguard Group Inc. increased its stake in Praxis Precision Medicines by 100.6% in the 1st quarter. Vanguard Group Inc. now owns 744,069 shares of the company’s stock worth $45,403,000 after acquiring an additional 373,131 shares during the last quarter. Boulder Hill Capital Management LP purchased a new stake in shares of Praxis Precision Medicines in the 1st quarter valued at about $256,000. Finally, StemPoint Capital LP bought a new stake in shares of Praxis Precision Medicines during the 1st quarter valued at about $1,641,000. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PRAX has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $151.00 price target on shares of Praxis Precision Medicines in a report on Thursday, November 7th. Wedbush increased their price objective on Praxis Precision Medicines from $40.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, August 14th. Oppenheimer boosted their target price on Praxis Precision Medicines from $143.00 to $163.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Guggenheim increased their price target on Praxis Precision Medicines from $155.00 to $170.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $146.33.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.